Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $1.164 million which beat the analyst consensus estimate of $1.000 million by 16.40 percent. This is a 15.10 percent decrease over sales of $1.371 million the same period last year.